Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).

Inclusion Criteria:

1. The patient is diagnosed as hepatocellular carcinoma(HCC);

2. The patient underwent radical operation of HCC within 8 weeks before enrollment;

3. The number of tumors≤2；

4. No cancer embolus in the main portal vein and first branch, hepatic duct and firstbranch, hepatic vein, inferior vena cava;

5. No portal lymph node metastasis；

6. No extra-hepatic metastasis;

7. Complete tumor resection without residual tumor at the surgical margins should beconfirmed by enhanced CT or MRI imaging within 4 week (including 4 weeks) afterradical operation;

8. If an increased serum AFP level was detected of the patient before the radicaloperation, the AFP level should be returned to normal in 8 weeks;

9. Child-Pugh Score ≤9;

10. ECOG Performance status (ECOG-PS) ≤2 ;

11. The expected survival time > 2 years;

12. Tests of blood,liver and kidney should meet the following criteria：

• WBC>3×109/L

• Neutrophil counts >1.5×109/L

• Hemoglobin ≥85 g/L

• Platelet counts≥50×109/L

• PT is normal or The extend time ＜3s

• BUN≤1.5 times the upper-limit ,

• Serum creatinine≤ 1.5 times of the upper-limit

13. Sign the informed consent.

Exclusion Criteria:

1. Women who is pregnant or during breast feeding or plan to pregnant in 2 years;

2. Extra-hepatic metastasis or liver residual tumor;

3. Cancer embolus in the main portal vein and first branch, Hepatic duct and firstbranch, hepatic vein, inferior vena cava;

4. 6 months before enrollment: the period of systemic and continuous use ofimmunomodulatory agents (such as interferon, thymosin, traditional Chinese medicine)was longer than 3 months;

5. 6 months before enrollment: the period of systemic and continuous use of theimmunosuppressive drugs (such as corticosteroids drug) was longer than 1 months;

6. Received any cell therapy (including NK, CIK, DC, CTL, stem cells therapy) in 6 monthsbefore enrollment;

7. Positive for HIV antibody or HCV antibody;

8. Have a history of immunodeficiency disease or autoimmune diseases (such as rheumatoidarthritis, Buerger's disease, multiple sclerosis and diabetes type 1);

9. Patient who suffered from other malignant tumor in 5 years before enrollment (exceptskin cancer, localized prostate cancer or cervix carcinoma);

10. . Patients with organ failure;

11. Patients with serious mental disease;

12. Drug addiction in 1year before enrollment (including alcoholics);

13. Participated in other clinical trials in 3 months before screening;

14. Other reasons the researchers think not suitable.